Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical supply

- PMLiVE

UK pharma Brexit pessimism deepens, as govt admits sector could be among worst hit

Political gridlock fuels fears ahead of 11 Dec vote

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

- PMLiVE

EU27 backs Brexit terms – now the hard part starts for May

House of Commons looks set to oppose the deal

- PMLiVE

As Brexit looms, UK medicines agency head Hudson announces departure

Search for successor must start in early 2019

- PMLiVE

UK and EU’s future relationship ‘must protect patients’

UK coalition concerned about regulation, data sharing, infectious disease controls

- PMLiVE

Brexit deal looks dead in the water – what now?

Fears of no deal Brexit return after MPs make opposition clear

- PMLiVE

Healthcare sector bullish despite political uncertainty

Targeted and gene therapies rated as major advances ahead of Jefferies conference in London

- PMLiVE

Decision time for Brexit

Pharma fears a no deal Brexit - but compromise deal has opponents on both sides

- PMLiVE

Brexit to blame as firm plans to leave UK for Ireland

Tax-inversion deal brought company to UK - now Brexit causes a re-think

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

GSK among businesses wooed as Brexit reckoning nears

Emma Walmsley to co-chair panel with supermarket CEO

- PMLiVE

Brexit: can pharma ‘take back control’ of the narrative?

Four Public Affairs managing director Sarah Jones talks to PME about the risks of Brexit - and how the sector musn't let the long-term issues become obscured

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links